Skip to main page content
U.S. flag

An official website of the United States government

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

2005
2025

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 1
2018 1
2019 1
2020 2
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Search Results

4 results

Results by year

Filters applied: . Clear all
Page 1
Long-term safety and effectiveness of natalizumab treatment in clinical practice: 10 years of real-world data from the Tysabri Observational Program (TOP).
Butzkueven H, Kappos L, Wiendl H, Trojano M, Spelman T, Chang I, Kasliwal R, Jaitly S, Campbell N, Ho PR, Licata S; Tysabri Observational Program (TOP) Investigators. Butzkueven H, et al. J Neurol Neurosurg Psychiatry. 2020 Jun;91(6):660-668. doi: 10.1136/jnnp-2019-322326. Epub 2020 Mar 31. J Neurol Neurosurg Psychiatry. 2020. PMID: 32234967 Free PMC article.
Neurofibromatosis type 2 and multiple sclerosis.
Helbing DL, Brodhun M, Tiedge O, Morrison H, Rosahl SK. Helbing DL, et al. Among authors: tiedge o. Mult Scler Relat Disord. 2020 Apr;39:101890. doi: 10.1016/j.msard.2019.101890. Epub 2019 Dec 9. Mult Scler Relat Disord. 2020. PMID: 31862656
Natalizumab treatment shows low cumulative probabilities of confirmed disability worsening to EDSS milestones in the long-term setting.
Trojano M, Butzkueven H, Kappos L, Wiendl H, Spelman T, Pellegrini F, Chen Y, Dong Q, Koendgen H, Belachew S; Tysabri® Observational Program (TOP) Investigators. Trojano M, et al. Mult Scler Relat Disord. 2018 Aug;24:11-19. doi: 10.1016/j.msard.2018.04.020. Epub 2018 May 2. Mult Scler Relat Disord. 2018. PMID: 29860197 Free article.